• +1-646-491-9876
    • +91-20-67278686

    Search

    Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017

    Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017

    • Report Code ID: RW0001881482
    • Category Life Sciences
    • No. of Pages 43
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Pipeline Review H2 2017

    Summary

    According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha) . This receptor activates NF-kappaB mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS) .

    The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase III Phase II Phase I Preclinical and Discovery stages are 1 2 1 2 and 2 respectively. Similarly the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules respectively. Report covers products from therapy areas Dermatology Immunology Gastrointestinal Central Nervous System Infectious Disease Oncology Ophthalmology and Respiratory which include indications Atopic Dermatitis Rheumatoid Arthritis Actinic (Solar) Keratosis Acute Lung Injury Acute Respiratory Distress Syndrome Crohn's Disease (Regional Enteritis) Genital Warts (Condylomata Acuminata) Inflammation Inflammatory Bowel Disease Melanoma Multiple Sclerosis Posterior Uveitis Psoriasis Soft Tissue Sarcoma and Warts.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
    - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Overview
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Companies Involved in Therapeutics Development
    Alvotech Iceland
    Eli Lilly and Company
    Eyevensys SAS
    G&E Herbal Biotechnology Co Ltd
    GlaxoSmithKline Plc
    Inflamalps SA
    Polaris Pharmaceuticals Inc
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Drug Profiles
    Atrosab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Antagonize TNFRSF1A for Inflammation-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EYS-606-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2862277-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3232094-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize TNF-R1 for Rheumatoid Arthritis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRT-100-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TNF-PEG 20-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Dormant Products
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Discontinued Products
    Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Product Development Milestones
    Featured News & Press Releases
    May 09 2017 Eyevensys Announces the First-in-Human Treatment with its Groundbreaking EyeCET ElectroTransfection Technology for Eye Diseases
    Apr 20 2017 Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
    Apr 11 2017 Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
    May 31 2016 Eyevensys appoints Dr. Patricia Zilliox an Experienced Ophthalmology Clinical Development Leader to Board of Directors
    Feb 18 2016 Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis
    May 13 2015 VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
    Oct 26 2012 South Africa first to grant IP protection in anti-warts
    Jan 02 2012 SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Alvotech Iceland H2 2017
    Pipeline by Eli Lilly and Company H2 2017
    Pipeline by Eyevensys SAS H2 2017
    Pipeline by G&E Herbal Biotechnology Co Ltd H2 2017
    Pipeline by GlaxoSmithKline Plc H2 2017
    Pipeline by Inflamalps SA H2 2017
    Pipeline by Polaris Pharmaceuticals Inc H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Alvotech Iceland
    Eli Lilly and Company
    Eyevensys SAS
    G&E Herbal Biotechnology Co Ltd
    GlaxoSmithKline Plc
    Inflamalps SA
    Polaris Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-1a-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-1a-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tumor-necrosis-factor-receptor-superfamily-member-1a-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments